Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Armata Pharmaceuticals, Inc.ARMP · Entity 6329 | Chief Business Officer | March 14, 2026 | March 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Armata Pharmaceuticals, Inc.
Report date March 14, 2026 · Filed March 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,461 |
Reported balance
After 2026-03-14 transaction · row 1
1 source rowRow 1 · 2026-03-14 · Tax withholding · Disposed 1,030 · Balance 9,461 F1: Represents shares that have been withheld by the Company to satisfy its income tax and withholding remittance obligations in connection with the net settlement of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares that have been withheld by the Company to satisfy its income tax and withholding remittance obligations in connection with the net settlement of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 14, 2026 Filed Mar 17, 2026 23:48 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | Tax withholdingCommon Stock | 1,030 | $10.54 | $10,856.20 |
DisclosureSEC source: 0001104659-26-029712 · tm269075-2_4seq1.xml · nonDerivative · entry 1 Kyme Pierre · CIK 0002028892 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,461 F1 · shares: Represents shares that have been withheld by the Company to satisfy its income tax and withholding remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| March 09, 2026 Filed Mar 12, 2026 01:18 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Options (Right to Buy) · Derivative | 183,142 | $0.00 Strike: $11.61 | $0.00 |
DisclosureSEC source: 0001104659-26-026588 · tm268588-9_4seq1.xml · derivative · entry 1 Kyme Pierre · CIK 0002028892 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 183,142 Underlying: Common Stock · 183,142 shares Expires 2036-03-09 F1 · derivative.exercise_date: Twenty-five percent (25%) of the Stock Options shall vest on March 9th of each of 2027, 2028, 2029, and 2030, in each case subject to continuous service through the applicable vesting date. Read SEC document |
| March 14, 2025 Filed Apr 25, 2025 20:06 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | Tax withholdingCommon Stock | 1,027 | $1.95 | $2,002.65 |
DisclosureSEC source: 0001104659-25-039414 · tm2513168-2_4seq1.xml · nonDerivative · entry 1 Kyme Pierre · CIK 0002028892 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,491 F1 · shares: Represents shares that have been withheld by the Company to satisfy its income tax and withholding remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:19 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Options (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0001104659-25-010561 · tm255864-5_4seq1.xml · derivative · entry 1 Kyme Pierre · CIK 0002028892 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2035-02-05 F1 · derivative.exercise_date: Twenty-five percent (25%) of the Stock Options shall vest on February 5th of each of 2026, 2027, 2028 and 2029, in each case subject to continuous service through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.